
Aura Announces S&P Global Upgrades Outlook to Positive B+ Rating on Larger Scale and Financial Performance
According to S&P, the upgraded outlook reflects several key factors: (i) the U.S. listing should allow accelerated growth for Aura without any increase in leverage; (ii) Aura track record of constructing small to medium projects and successfully turning around older assets; and (iii) record high gold prices that are propelling free operating cash flow amid the company's significant expansion capital expenditure (capex) program.
Over the next 12 months, S&P also indicates the possibility of an upgrade if the company succeeds in growing its scale, namely with the ramp up of Borborema, integrating Serra Grande, and starting another project in that timeframe, while it keeps gross debt to EBITDA below 2.0x. However, there can be no assurance whether S&P will take such action with respect to our ratings in the future.
The full report can be accessed on the S&P website or on the Company's investor relations website at
https://www.auraminerals.com/en/investors/
.
About Aura 360° Mining
Aura is focused on mining in complete terms – thinking holistically about how its business impacts and benefits every one of our stakeholders: our company, our shareholders, our employees, and the countries and communities we serve. We call this 360° Mining.
Aura is a company focused on the development and operation of gold and base metal projects in the Americas. The Company's five operating assets include the Minosa gold mine in Honduras; the Almas, Apoena, and Borborema gold mines in Brazil; and the Aranzazu copper, gold, and silver mine in Mexico. Additionally, the Company owns Era Dorada, a gold project in Guatemala; Tolda Fria, a gold project in Colombia; and three projects in Brazil: Matupá, which is under development; São Francisco, which is in care and maintenance; and the Carajás copper project in the Carajás region, in the exploration phase.
Caution Regarding Forward-Looking Information and Statements
This press release includes certain statements and information that may constitute 'forward-looking information' within the meaning of applicable Canadian securities laws and/or 'forward-looking statements' within the meaning of applicable United States securities laws (collectively, 'forward-looking statements'). Some of the matters discussed concerning our business operations include estimates and forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or future performance and reflect the Company's current estimates, predictions, expectations or beliefs regarding future events and include, without limitation, statements with respect to: accelerated growth for Aura without any increase in leverage; the propelling of free operating cash flow; the expansion of the Company's capital expenditure program; upside at Serra Grande; ramp up at Borborema; and new expansion projects. Often, but not always, forward-looking statements may be identified by the use of words such as 'expects', 'anticipates', 'plans', 'projects', 'estimates', 'assumes', 'intends', 'strategy', 'goals', 'objectives' or variations thereof or stating that certain actions, events or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved, or the negative of any of these terms and similar expressions.
Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements in this press release are based upon, without limitation, estimates and assumptions relating to general business, economic and market conditions.
These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Readers are cautioned that reliance on such information may not be appropriate for other purposes.
The Company does not undertake to update any forward-looking statement or forward-looking information, except in accordance with applicable securities laws.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Business Insider
a few seconds ago
- Business Insider
Morgan Stanley sees a 'rolling recovery' underway that's set to drive the stock market up 12% by mid-2026
Morgan Stanley sees the outlook for corporate earnings boosting stocks to new heights in the coming 12 months. After markets were battered in April amid Donald Trump's tariff announcements, earnings are getting a boost from a handful of sources. The bank said that April's price action represented the end of a "rolling earnings recession" that began in 2022. "Now, we appear to be transitioning to a rolling recovery backdrop aided by positive operating leverage, AI adoption, dollar weakness, cash tax savings from the OBBBA, easy growth comparisons, pent up demand for many sectors, and a high probability of Fed cuts by 1Q26," the bank's chief investment office Michael Wilson wrote. The bank sees the S&P 500 rising to 7,200 in its bull case, a 12% jump from Friday's close. It also said the probability of such an outcome for the broad index is on the rise. Wilson said that high valuations that some observers have been fretting over appear to be justified. The bank recommends the industrials sector as its top pick, even after it has been the top-performing sector of the S&P 500 year-to-date. Major market indexes have risen steadily over the past week, with the S&P 500 closing at record highs on July 25. The index is up 9% year-to-date. Morgan Stanley's prediction comes as economic uncertainty appears to be easing. With President Donald Trump announcing a new trade agreement with the European Union and the Federal Reserve expected to cut interest rates later this year, investors may be feeling more confident in the market's strength. "The historically sharp inflection we're seeing in earnings revisions breadth confirms this process is underway," the bank stated, noting that it sees this phenomenon as underappreciated.
Yahoo
28 minutes ago
- Yahoo
BMO Capital Cuts Sarepta Therapeutic (SRPT) PT to $25 from $50
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the most undervalued stocks to buy and hold for 3 years. On July 22, BMO Capital adjusted its price target for Sarepta to $25 from $50, while maintaining a Market Perform rating. The decision was made as a response to the temporary pause in Sarepta's ELEVIDYS program. BMO Capital views this pause as an optimal decision, as refusal to comply with the FDA could lead to regulatory risks across Sarepta's programs and hinder ELEVIDYS' uptake. The temporary halt in ELEVIDYS shipments in the US began at the close of business on July 22 to allow Sarepta and the FDA to complete the safety labeling update process following a patient death linked to acute liver failure and other safety concerns. A laboratory technician in a white coat holding a microscope and examining a vial of biopharmaceuticals. In Q1 2025, the company reported total net product revenue of $612 million, representing a 70% growth over the same quarter last year. ELEVIDYS revenue saw a 180% increase year-over-year and reached $375 million. The PMO (peptide-conjugated phosphorodiamidate morpholino oligomer) franchise revenue increased by 5% over the prior year and reached $237 million. Total revenues for the quarter were $745 million, which was an 80% increase year-over-year. Sarepta Therapeutics Inc. (NASDAQ:SRPT) is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. While we acknowledge the potential of SRPT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
28 minutes ago
- Yahoo
Lululemon Expands Global Footprint with First Italy Store in Milan
Lululemon Athletica Inc. (NASDAQ:LULU) is one of the cheap Canadian stocks to buy now. On July 18, Lululemon announced that it is expanding its international presence with the opening of its first store in Italy, with the launch on July 19, in Milan's prominent shopping district, located at Vittorio Emanuele II 24/28. The Milan store spans ~5,700 square feet across 2 floors and will offer a carefully curated environment for shoppers. It will feature distinct sections showcasing Lululemon's signature technical innovations and both men's and women's collections, all designed for high-performance and style suitable for activities like yoga, running, training, tennis, and golf. A store employee in an athletic apparel store restocking merchandise. The store's architectural concept is expected to blend Italian design heritage with contemporary materials, incorporating a notable Lululemon Glide sculptural facade. Lululemon Athletica Inc. (NASDAQ:LULU) designs, distributes, and retails technical athletic apparel, footwear, and accessories for women and men under the lululemon brand in the US, Canada, Mexico, China Mainland, Hong Kong, Taiwan, Macau, and internationally. While we acknowledge the potential of LULU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.